ImmunityBio (IBRX) announced that it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80M before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96M. Piper Sandler & Co. is acting as the exclusive placement agent for the registered direct offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update
- ImmunityBio’s Novel Approach to Combat Lymphopenia: A Market Game-Changer?
- ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update
- ImmunityBio’s Strategic Advancements and Market Potential Justify Buy Rating
- ImmunityBio Approves 2025 Equity Incentive Plan